American Association for Cancer Research
epi-23-0331_supplementary_figure_s5_suppsf5.docx (162.03 kB)

Supplementary Figure S5 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes

Download (162.03 kB)
journal contribution
posted on 2023-10-02, 07:40 authored by Ji-Qing Chen, Lucas A. Salas, John K. Wiencke, Devin C. Koestler, Annette M. Molinaro, Angeline S. Andrew, John D. Seigne, Margaret R. Karagas, Karl T. Kelsey, Brock C. Christensen

Supplementary Figure S5: Kaplan-Meier analysis of 10-year overall survival based on the grouping results from both partDSA and SS-RPMM in all NMIBC patients [For Hannum age acceleration]


National Institutes of Health (NIH)

Congressionally Directed Medical Research Programs (CDMRP)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

National Institute of General Medical Sciences (NIGMS)

United States Department of Health and Human Services

Find out more...



Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival. Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93–0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23–1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04–1.41), neutrophil (HR = 1.04, 95% CI = 1.03–1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03–1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention





    Ref. manager